Patient Feedback for MDS: Insights and Closing Remarks
Medical experts offer their insights and closing remarks regarding patient feedback for MDS.
Oral vs. IV HMAs: Considerations and Patient Guidance
Medical experts discuss considerations and patient guidance for oral and IV HMAs.
Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact
Medical experts discuss innovations and future directions in treatments for higher-risk MDSMedical experts offer patient perspectives on advantages and disadvantages of using oral HMAs vs injectable HMAs.
Innovations and Future Directions in Higher Risk MDS Treatments
Medical experts discuss innovations and future directions in treatments for higher-risk MDS.
HMA Persistence and Effectiveness in Higher Risk MDS
Medical experts offer insights on the persistence and effectiveness of HMAs in patients with higher-risk MDS.
Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS
Medical experts discuss convenience and efficacy in higher-risk MDS regarding oral vs injectable HMAs.
ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS
Medical experts discuss the data gathered from the ASCERTAIN trial.
Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial
Medical experts offer insights on the COMMANDS trial findings.
Choosing MDS Therapies: Risk-Based Approaches
Medical experts discuss risk-based approaches to choosing MDS therapies.
Advances in MDS Classification and Molecular Understanding
After a brief introduction, medical experts discuss advances in MDS classification and molecular understanding.
Future Management of Myelodysplastic Syndromes
Panelists look toward the future management of myelodysplastic syndromes with respect to novel agents and treatment pathways.
Interchangeability Between Oral and IV Agents in HR-MDS
Experts reflect on interchangeability between oral and intravenous therapy in patients with higher-risk myelodysplastic syndromes.
Practical Considerations for the Use of HMAs in Higher-Risk MDS
Shared insight on the historical and current use of hypomethylating agents in patients with myelodysplastic syndromes.
Impact of an Oral HMA on the HR-MDS Treatment Landscape
Perspectives on the use of oral HMA therapy in higher-risk myelodysplastic syndromes, and how this has improved patient care.
Higher-Risk MDS: When to Use HMA Therapy or Lenalidomide
Expert panelists discuss when it’s appropriate to consider or continue ESA therapy or blood transfusions in patients with MDS.
Goals of Therapy for Patients With Myelodysplastic Syndromes
Panelists share insight on therapeutic goals when treating patients with myelodysplastic syndromes.
Factors in Selecting Therapy for Myelodysplastic Syndromes
A brief review of disease and patient factors that influence the selection of therapy for myelodysplastic syndromes.
Considering the Role of ESAs and Blood Transfusions in MDS Management
Reflections on the historical use of ESAs and blood transfusions to treat patients with myelodysplastic syndromes.
Gaps in the Diagnosis and Treatment of Myelodysplastic Syndromes
Experts consider shortcomings in the identification and management of myelodysplastic syndromes.
Educating Patients and Caregivers on MDS Subtypes
Practical perspectives on how to communicate MDS subclassifications with affected patients and caregivers.
Identifying Myelodysplastic Syndromes Subtypes
Expert perspectives on the changes in MDS subclassifications as understandings of the disease have evolved.
Approaching Patient and Caregiver Education on Myelodysplastic Syndromes
Shared insight on how to best educate patients and caregivers on the broad nature of myelodysplastic syndromes.
Understanding the Nature of Myelodysplastic Syndromes
A panel of experts discuss the complex nature of myelodysplastic syndromes and concurrent subclassifications.
